Cinacalcet HCl

Catalog No.S1260 Synonyms: AMG-073 HCl

Cinacalcet HCl Chemical Structure

Molecular Weight(MW): 393.87

Cinacalcet HCl represents a new class of compounds for the treatment of hyperparathyroidism.

Size Price Stock Quantity  
In DMSO USD 160 In stock
USD 120 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

1 Customer Review

  • A. SK-N-LP cells stably transfected with pCMV-GFP or pCMV-CaSR-GFP were grown in serum deprivation media for 16 hours. They were then exposed to cinacalcet for 24 hours at indicated doses in the same media containing 0.5 mM CaCl2 . Total proteins were isolated from floating and adherent cells to conduct immunoblots.

    Oncotarget, 2016, 7(13):16112-29. Cinacalcet HCl purchased from Selleck.

Purity & Quality Control

Choose Selective CaSR Inhibitors

Biological Activity

Description Cinacalcet HCl represents a new class of compounds for the treatment of hyperparathyroidism.
CaSR [1]
2.8 μM(EC50)
In vitro

AMG-073 represents a new class of compounds for the treatment of hyperparathyroidism known as calcimimetics, which reduce parathyroid hormone (PTH) synthesis and secretion by increasing the sensitivity of the parathyroid calcium-sensing receptor (CaR) to extracellular calcium. AMG-073 has potential advantages as a therapy for secondary hyperparathyroidism because it mimics the effects of extracellular calcium to suppress PTH secretion, even in the presence of hyperphosphatemia, without the risk of causing hypercalcemia and/or hyperphosphatemia. AMG-073 produces a concentration-dependent increase in cytoplasmic calcium in human embryonic kidney cells expressing the CaSR. In bovine parathyroid cells and a buffer containing calcium 0.5 mM, AMG 073 (3 nM – 1 μM) produces a concentration-dependent decrease in PTH levels with IC50 of 27 nM. [2]

In vivo AMG-073 orally administrated to normal rats at dose of 1, 3, 10, and 30 mg/kg in 20% sulfobutyl ether β-cyclodextrin sodium produces a significant dose-dependent reduction in PTH levels for 1 to 4 hours after administration. At 8 hours, the 10- and 30-mg/kg doses of AMG-073 produces significant reductions in PTH levels compared with controls that disappears by 24 hours. Significant dose-dependent reduction in serum calcium levels are observed at 4, 8, and 24 hours after oral administration of AMG-073 3, 10, and 30 mg/kg, respectively. A transient reduction in serum phosphorus levels is observed only with the highest dose of AMG-073. In addition, increased calcitonin levels that paralleled PTH suppression are observed with AMG-073 40 mg/kg in rats. As in normal rats, a rapid dose-dependent reduction in PTH and calcium levels is observed in 5 of 6 nephrectomized rats after oral administration of AMG-073. In addition, oral AMG-073 at 5 and 10 mg/kg for 4 weeks significantly reduces parathyroid weight compared with controls. [2]


Solubility (25°C)

In vitro DMSO 79 mg/mL (200.57 mM)
Ethanol 33 mg/mL (83.78 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 393.87


CAS No. 364782-34-3
Storage powder
in solvent
Synonyms AMG-073 HCl

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00325104 Completed Hypercalcemia|Familial Primary Hyperparathyroidism National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) May 9 2006 Phase 3
NCT02138838 Terminated Chronic Kidney Disease Secondary Hyperparathyroidism Amgen November 7 2014 Phase 3
NCT03123406 Recruiting Hyperparathyroidism; Secondary Renal Kyowa Hakko Kirin China Pharmaceutical Co.LTD. April 25 2017 Phase 4
NCT01439867 Terminated Chronic Kidney Disease|Hyperparathyroidism Secondary Amgen June 22 2012 Phase 2
NCT00345839 Completed Secondary Hyperparathyroidism|Chronic Kidney Disease Amgen August 22 2006 Phase 3
NCT02338934 Unknown status Secondary Hyperparathyroidism Penang Hospital Malaysia|Ministry of Health Malaysia January 2015 Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

CaSR Signaling Pathway Map

Related CaSR Products

Tags: buy Cinacalcet HCl | Cinacalcet HCl ic50 | Cinacalcet HCl price | Cinacalcet HCl cost | Cinacalcet HCl solubility dmso | Cinacalcet HCl purchase | Cinacalcet HCl manufacturer | Cinacalcet HCl research buy | Cinacalcet HCl order | Cinacalcet HCl mouse | Cinacalcet HCl chemical structure | Cinacalcet HCl mw | Cinacalcet HCl molecular weight | Cinacalcet HCl datasheet | Cinacalcet HCl supplier | Cinacalcet HCl in vitro | Cinacalcet HCl cell line | Cinacalcet HCl concentration | Cinacalcet HCl nmr
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID